Summit Therapeutics: Ivonescimab’s De-Risked Regulatory Path and Multi-Indication Upside Support $40 Target and Buy Rating

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Summit Therapeutics today and set a price target of $40.00.

Mitchell Kapoor has given his Buy rating due to a combination of factors tied to Summit Therapeutics’ lead asset ivonescimab and its growing regulatory momentum. He views the FDA’s acceptance of the Biologics License Application for ivonescimab in EGFR‑mutated NSCLC as a meaningful de‑risking event, since it confirms the filing is complete enough to merit full review and sets a clear timeline toward a potential U.S. approval decision by November 2026. In his assessment, the EGFR‑mutated indication is additive but not essential to the investment thesis, which is primarily anchored in ivonescimab’s potential to outperform pembrolizumab in first‑line PD‑L1–positive NSCLC and to show activity in biologically challenging post‑TKI settings. He expects near‑term share performance to be driven more by upcoming overall survival data from the HARMONi‑2 trial than by procedural aspects of the EGFR filing, and interprets prior mixed OS reads as more reflective of trial design and statistical noise than a hard cap on efficacy.

Kapoor’s valuation work, based on a discounted cash flow model, yields an enterprise value of roughly $34 billion and supports a 12‑month price target of $40 per share, underpinned by an 8% discount rate and 4% terminal growth rate. These assumptions reflect his confidence in the ivonescimab data set and the well‑validated nature of PD‑1 as a target, informed by Keytruda’s extensive approval history. He incorporates multiple potential future indications by assigning differentiated probabilities of approval across NSCLC, triple‑negative breast cancer, colorectal cancer, and head and neck cancer, which together create a diversified set of value drivers. While he acknowledges key risks—including clinical delays, possible trial failures, and dilution risk—he concludes that the upside from ivonescimab’s clinical profile and commercial opportunity more than compensates for these uncertainties, justifying the Buy recommendation.

Kapoor covers the Healthcare sector, focusing on stocks such as Halozyme, Neurogene, and Sarepta Therapeutics. According to TipRanks, Kapoor has an average return of 5.9% and a 40.22% success rate on recommended stocks.